European Journal of Cancer最新文献

{"title":"Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial","authors":"Lingyun Sun ,&nbsp;Yun Xu ,&nbsp;Nan Chen ,&nbsp;Chunze Zhang ,&nbsp;Aiwen Wu ,&nbsp;Huaqing Wang ,&nbsp;Yutong Fei ,&nbsp;Peng Shu ,&nbsp;Dechang Diao ,&nbsp;Jianping Cheng ,&nbsp;Yuping Chu ,&nbsp;Tianshu Liu ,&nbsp;Wei Wang ,&nbsp;Ye Yuan ,&nbsp;Baozhu Zeng ,&nbsp;Yang Cao ,&nbsp;Shundong Cang ,&nbsp;Huijuan Cao ,&nbsp;Tong Zhang ,&nbsp;Yang Zheng ,&nbsp;Yufei Yang","doi":"10.1016/j.ejca.2024.115109","DOIUrl":"10.1016/j.ejca.2024.115109","url":null,"abstract":"<div><h3>Purpose</h3><div>Many cancer patients express interest in using herbal medicine during chemotherapy, but little is known about its benefits and risks. This study aimed to evaluate the effects of the Chinese herbal medicine JianPi-BuShen formula (JPBS) on adjuvant chemotherapy completion in colon cancer patients.</div></div><div><h3>Patients and methods</h3><div>This multi-center, phase III, randomized, placebo-controlled trial included patients with stage II (high risk for recurrence) and stage III colon cancer following surgery, planning to receive CAPOX (capecitabine and oxaliplatin) chemotherapy. Patients were randomized 1:1 to receive either JPBS or a placebo. The primary outcome was the completion rate of planned chemotherapy cycles. Secondary outcomes included relative dose intensity (RDI), chemotherapy-induced toxicities, quality of life (measured by the Edmonton Symptom Assessment System - ESAS), adverse events (AEs), and serious AEs (SAEs). Predefined subgroup analyses were performed by age (&gt;65/≤65) and TNM stage (II/III).</div></div><div><h3>Results</h3><div>A total of 376 participants were analyzed, with a median age of 60.3 years; 56.9 % were male, and 67.6 % had stage III disease. Chemotherapy completion was significantly higher in the JPBS group than in the placebo group (63.0 % vs. 47.6 %, P = 0.003). Oxaliplatin RDI was also higher in the JPBS group (P = 0.049). Subgroup analyses showed JPBS significantly improved completion rates for stage II patients (73.0 % vs. 42.4 %, P = 0.001) and younger patients (66.9 % vs. 48.8 %, P = 0.004). JPBS reduced grade ≥ 2 vomiting (3.8 % vs. 6.4 %, P = 0.007) but increased grade ≥ 2 thrombocytopenia (16.2 % vs. 12.4 %, P = 0.012). Quality of life improved in stage II and younger patients.</div></div><div><h3>Conclusion</h3><div>JPBS improved chemotherapy completion rates in stage II and younger colon cancer patients without compromising tolerability. Further research is needed to explore its mechanisms and long-term effects.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115109"},"PeriodicalIF":7.6,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial","authors":"Annie Xiao ,&nbsp;Xiaochen Li ,&nbsp;Chongkai Wang ,&nbsp;Jian Ye ,&nbsp;Marwan Fakih","doi":"10.1016/j.ejca.2024.115111","DOIUrl":"10.1016/j.ejca.2024.115111","url":null,"abstract":"<div><h3>Background</h3><div>Combination regorafenib, ipilimumab, and nivolumab (RIN) was evaluated in a phase 1 nonrandomized study (NCT04362839) of refractory microsatellite stable (MSS) metastatic colorectal cancer. Promising antitumor activity was previously reported in the non-liver metastatic (NLM) population. This updated analysis describes long-term survival outcomes in the NLM cohort and highlights durable remissions with potential cure following completion of RIN therapy.</div></div><div><h3>Methods</h3><div>Between May 2020 and January 2022, 39 patients with refractory MSS metastatic colorectal cancer were enrolled. Patients received RIN until progression, unacceptable toxicity, or completion at two years. The primary endpoint was recommended phase 2 dose (RP2D) selection. Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) at the RP2D level.</div></div><div><h3>Results</h3><div>22 patients with refractory non-liver metastatic MSS colorectal cancer were treated at the RP2D of RIN. ORR was 36.4 % (8/22 patients), and median PFS was 5.0 months (95 % CI: 3–9). After a median follow-up of 42 months, the 1-, 2-, and 3-year PFS rates were 24.1 %, 24.1 %, and 19.3 % by RECIST. The median OS was 27.5 months (95 % CI: 14.0 to NE). At data cutoff, 6 patients had ongoing clinical benefit, including 3 responders who remain disease-free &gt; 18 months after treatment completion.</div></div><div><h3>Conclusion</h3><div>With extended follow-up, RIN combination therapy demonstrated durable clinical benefit in a subset of patients with NLM MSS metastatic colorectal cancer, including potential cure in 3 responders who remain disease-free &gt; 18 months after treatment completion.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115111"},"PeriodicalIF":7.6,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of men with synchronous metastatic prostate cancer diagnosis – A nationwide 26-year temporal analysis","authors":"Hein V. Stroomberg ,&nbsp;J. Thomas Helgstrand ,&nbsp;Klaus Brasso ,&nbsp;Signe Benzon Larsen ,&nbsp;Andreas Røder","doi":"10.1016/j.ejca.2024.115110","DOIUrl":"10.1016/j.ejca.2024.115110","url":null,"abstract":"<div><h3>Background</h3><div>Evolving imaging modalities, increased awareness, and prostate-specific antigen testing in men with synchronous metastatic prostate cancer (mHSPC) are expected to have prolonged survival. Here we analyze trends in survival among men diagnosed with synchronous metastatic prostate cancer in Denmark.</div></div><div><h3>Methods</h3><div>Here, we included all men diagnosed with mHSPC (N = 12,017) in Denmark between January 1st, 1995, and December 31st, 2021. Men were followed until December 31st, 2022. Median time to death was calculated by the Kaplan Meier method and the 3-year risk of prostate cancer death per calendar year was estimated by the Aalen-Johansen estimator from time of diagnosis.</div></div><div><h3>Findings</h3><div>Median follow-up was 9 years (IQR: 4–15), from 2015 59 % of the men with mHSPC had treatment beyond androgen depletion therapy. Median survival increased from 1.7 years (IQR: 1·3–2·0) to 3.8 years (IQR: 3·3–4·2) in men diagnosed in 1995 and 2018, respectively (p &lt; 0·001), after which median survival was not reached. The prostate cancer-specific mortality three years after diagnosis decreased from 66 % (95 %CI: 60–72) in 1995 to 28 % (95 %CI: 25–32) in 2019 (p &lt; 0·001). From the period 1995–1999 to 2015–2021 median overall survival increased from 1·7 years (IQR: 0·8–3·7) to 4·5 years (IQR: 2·4-not reached; p &lt; 0·001) in men age &lt; 65 years and from 1·5 years (IQR: 0·7–2·9) to 3·1 years (IQR: 1·6–5·7; p &lt; 0.001) in men older than 74 years at diagnosis.</div></div><div><h3>Interpretation</h3><div>The improved survival suggests that, among other contributing factors, implementing novel therapies has likely been efficacious outside the clinical trial setting. Still, most men diagnosed with synchronous metastatic prostate cancer will die of prostate cancer. As such the need for life-prolonging and age-tailored treatment trials remains evident.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115110"},"PeriodicalIF":7.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142593610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial","authors":"Luca Livraghi ,&nbsp;Francesca Martella ,&nbsp;Matteo Ghilli ,&nbsp;Catia Angiolini ,&nbsp;Simonetta Magnanini ,&nbsp;Erica Moretti ,&nbsp;Carmelo Bengala ,&nbsp;Emanuela Risi ,&nbsp;Elena Molinara ,&nbsp;Ilaria Pazzagli ,&nbsp;Luca Malorni ,&nbsp;Sara Donati ,&nbsp;Stefano Gabellini ,&nbsp;Angelo Martignetti ,&nbsp;Piergiorgio Giannessi ,&nbsp;Giuseppina Sanna ,&nbsp;Leonardo Barellini ,&nbsp;Chiara Biagioni ,&nbsp;Luca Boni ,&nbsp;Simonetta Bianchi ,&nbsp;Laura Biganzoli","doi":"10.1016/j.ejca.2024.115108","DOIUrl":"10.1016/j.ejca.2024.115108","url":null,"abstract":"<div><h3>Background</h3><div>Data published in 2015 showed that patients with early breast cancer (EBC) and a low-risk (LR) Recurrence Score® (RS) result by the 21-gene Oncotype DX® assay (“the test”) did not derive benefit from adding chemotherapy (CT) to endocrine therapy (HT), while those with a high-risk (HR) RS result did. However, the role of CT remained uncertain in patients with intermediate-risk (IR) cancers. We designed a study to assess the test’s ability to categorize patients with EBC with uncertain biological behavior into the groups (LR and HR) for which the value of additional chemotherapy was defined.</div></div><div><h3>Methods</h3><div>The POST trial was a multicenter, prospective cohort study conducted in 14 Breast Centers of the Tuscany region of Italy. Consecutive patients with pT1–2 pN0-N1mi hormone receptor-positive/HER2-negative EBC and uncertain biological behavior based on standard parameters were enrolled. Patients were categorized based on RS results into LR, IR, and HR groups if RS result was &lt; 11, 11–25, and &gt; 25, respectively. Treatment recommendations by multidisciplinary meeting assessed before and after RS results were available.</div></div><div><h3>Results</h3><div>Of 246 tested samples, 78 were classified as LR or HR, with most of the patients (65.4 %) being at IR. Following test results, the recommendation changed in 15.9 % of cases. Among patients initially recommended for CT or for discussion about the role of CT, respectively 64.3 % and 75.9 % ultimately received recommendation for HT alone.</div></div><div><h3>Conclusions</h3><div>Our study suggests that RS results can refine treatment decisions for patients with EBC exhibiting uncertain biological behavior initially recommended or considered for CT.</div><div>(250/250)</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115108"},"PeriodicalIF":7.6,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward","authors":"Luca Locher ,&nbsp;Miquel Serra-Burriel ,&nbsp;Dario Trapani ,&nbsp;Emanuel Nussli ,&nbsp;Kerstin N. Vokinger","doi":"10.1016/j.ejca.2024.115106","DOIUrl":"10.1016/j.ejca.2024.115106","url":null,"abstract":"<div><div>Cancer drugs have accumulated the most approvals over the past years. Overall survival (OS) is considered the gold standard for cancer trial outcomes. However, its use has declined over the past years, in favor of surrogate endpoints, such as progression-free survival (PFS). PFS allows to assess outcomes earlier and, thus, accelerates approval of cancer drugs. Previous studies have demonstrated a poor correlation between PFS and OS. Using simulation models, we examined why PFS usually overestimates survival benefit. We created a publicly accessible <span><span>web application</span><svg><path></path></svg></span> that allows users to run the simulations with different parameter settings. Based on the findings, we propose that assessment of preliminary evidence should be based on a combination of OS result and prognostic scores that reflect the health status of surviving patients.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115106"},"PeriodicalIF":7.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma” [Eur J Cancer, 207, August 2024, 114173]","authors":"Hujian Hong ,&nbsp;Yanli Qu","doi":"10.1016/j.ejca.2024.115101","DOIUrl":"10.1016/j.ejca.2024.115101","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115101"},"PeriodicalIF":7.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158]","authors":"Anna Kron ,&nbsp;Matthias Scheffler ,&nbsp;Marcel Wiesweg ,&nbsp;Horst-Dieter Hummel ,&nbsp;Jonas Kulhavy ,&nbsp;Stefan Gatteloehner ,&nbsp;Jens Kollmeier ,&nbsp;Christoph Schubart ,&nbsp;Thorben Groß ,&nbsp;Melanie-Christin Demes ,&nbsp;Stefanie Keymel ,&nbsp;Maria Joosten ,&nbsp;Sabine Merkelbach-Bruse ,&nbsp;Christina Bianca Woelwer ,&nbsp;Amanda Tufman ,&nbsp;Diego Kauffmann-Guerrero ,&nbsp;Katharina Oeser ,&nbsp;Melanie Zehaczek ,&nbsp;Ulli Jeratsch ,&nbsp;Juergen Wolf","doi":"10.1016/j.ejca.2024.115074","DOIUrl":"10.1016/j.ejca.2024.115074","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115074"},"PeriodicalIF":7.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study","authors":"Carmine Valenza ,&nbsp;Dario Trapani ,&nbsp;Paola Zagami ,&nbsp;Gabriele Antonarelli ,&nbsp;Luca Boscolo Bielo ,&nbsp;Eleonora Nicolò ,&nbsp;Joana Mourato Ribeiro ,&nbsp;Lorenzo Guidi ,&nbsp;Carolina Reduzzi ,&nbsp;Martina Spotti ,&nbsp;Laura Adamoli ,&nbsp;Javier Cortès ,&nbsp;Barbara Pistilli ,&nbsp;Sara M. Tolaney ,&nbsp;Naoto Ueno ,&nbsp;Rachel M. Layman ,&nbsp;Massimo Cristofanilli ,&nbsp;Lisa A. Carey ,&nbsp;Elisabetta Munzone ,&nbsp;Carmen Criscitiello ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.ejca.2024.115097","DOIUrl":"10.1016/j.ejca.2024.115097","url":null,"abstract":"<div><h3>Background</h3><div>Inflammatory breast cancer (IBC) is the most aggressive clinical presentation of breast cancer, recapitulating a specific biology with more immune-vulnerability than non-IBC. Patients with metastatic, triple-negative IBC (mTN-IBC) receive immune checkpoint inhibitors (ICIs) and chemotherapy, similarly to patients with triple-negative non-IBC. However, the benefit derived from ICI incorporation in this rare type of breast cancer is unknown.</div></div><div><h3>Methods</h3><div>We conducted a multicenter, international, retrospective, cohort study to evaluate the activity of ICIs in patients with metastatic, triple-negative, primary IBC, who received ICIs plus first line chemotherapy from January 2015 to April 2023. A sample size of 42 patients allowed to detect an increase in 6-months real-world progression-free survival (rwPFS) rate from 40 % with only chemotherapy to 60 % with ICI and chemotherapy.</div></div><div><h3>Results</h3><div>41 patients from eight international IBC referral centers were included (61 % with primary, <em>de novo</em> mTN-IBC, 61 % with visceral disease). All received ICIs plus first line chemotherapy and 24 % underwent breast surgery and/or locoregional radiotherapy. After a median follow-up of 19.3 months, the 6-months rwPFS rate was 30 % (95 % Confidence Interval [CI], 17–45 %), the median rwPFS was 3.3 months (95 % CI: 2.2–5.4), the median overall survival was 15.7 months (95 % CI: 6.8–16.3).</div></div><div><h3>Conclusions</h3><div>This one-sample analysis showed a poor outcome of patients with mTN-IBC, despite the treatment with ICI, in contrast with the expected benefit based on preclinical evidence of immune-vulnerability of IBC. These results suggest the need to further investigate the role of immunotherapy in this aggressive and rare type of breast cancer presentation.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115097"},"PeriodicalIF":7.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142561157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations","authors":"Claudio Sini,&nbsp;Alessandro Di Federico,&nbsp;Paolo Bironzo,&nbsp;Andrea De Giglio,&nbsp;Francesco Gelsomino","doi":"10.1016/j.ejca.2024.115085","DOIUrl":"10.1016/j.ejca.2024.115085","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115085"},"PeriodicalIF":7.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility analysis of using patient-derived tumour organoids for treatment decision guidance in locally advanced head and neck squamous cell carcinoma","authors":"Anne-Sophie Fisch ,&nbsp;Ana Pestana ,&nbsp;Vanessa Sachse ,&nbsp;Christian Doll ,&nbsp;Elena Hofmann ,&nbsp;Max Heiland ,&nbsp;Theresa Obermueller ,&nbsp;Jan Heidemann ,&nbsp;Steffen Dommerich ,&nbsp;Diana Schoppe ,&nbsp;Simon Schallenberg ,&nbsp;Iris Piwonski ,&nbsp;Eric Blanc ,&nbsp;Ingeborg Tinhofer","doi":"10.1016/j.ejca.2024.115100","DOIUrl":"10.1016/j.ejca.2024.115100","url":null,"abstract":"<div><h3>Background</h3><div>Current treatment for head and neck squamous cell carcinoma (HNSCC) involves surgery, radiotherapy, and chemotherapy. Despite aggressive multimodal approaches, tumour recurrence occurs in 40–60 % of cases, leading to poor survival outcomes. HNSCC lacks common genetic drivers for tailored therapies, and reliable biomarkers for treatment selection are scarce. We investigated the procedural requirements for incorporating drug- and radiosensitivity screens in patient-derived organoids (PDOs) within a clinical trial framework.</div></div><div><h3>Patients and methods</h3><div>Fresh tumour samples (<em>N</em> = 198) from 186 HNSCC patients were included. Success rates of organoid establishment were correlated with clinical and procedural parameters. Timelines for establishment of PDO cultures were determined, and their long-term growth potential assessed by serial passaging. Additionally, we conducted whole exome sequencing on matched tumour-organoid pairs. Three PDO models were employed to establish radiosensitivity assays.</div></div><div><h3>Results</h3><div>In total, PDO models displaying histomorphological features and genomic alterations of parental tumours were successfully established for 35 % of patient tumours. Success rates rose to 77 % for samples with a tumour cell content of 30 % or higher. Advanced patient age, prior radiotherapy, and delays in tissue processing were identified as negative predictors for engraftment. The estimated time interval needed for screens was compatible with PDO-guided selection of curative-intent radiotherapy regimens.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that with high-quality samples and efficient tissue processing, PDO screens can be successfully performed in 77 % of HNSCC patients. Given the procedural challenges involved, future clinical trials aiming to the utility of PDOs for guiding treatment decisions should consider implementing centralised PDO screening.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115100"},"PeriodicalIF":7.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}